Lichenoid/Interface cutaneous eruptions to IVIg with the primary infusion may be related to the re-regulation of anti-idiotype network.
BACKGROUND
Intravenous immunoglobulin (IVIg) has been used in recent years to treat an increasing number of autoimmune diseases to decrease cytokine secretion and to neutralize toxins, in addition to the therapy of immunodeficiency disorders. In addition to angioedema-like hypersensitivity eruptions, there have been reports of eczematous, purpuric, petechial/purpuric, and vasculitic reactions to IVIg; however, there has been only one previous report of a case in which the patient developed a lichenoid dermatitis after infusion of IVIg.


METHODS
We present two patients with chronic inflammatory, demyelinating polyneuropathy, who after the first course of IVIg developed a folliculocentric interface/lichenoid eruption that cleared without therapy or with topical steroids. The eruption did not recur with subsequent IVIg infusions in either patient.


CONCLUSIONS
The multiple diverse effects of IVIg on the immune system, and the re-regulation of the anti-idiotype network with repeat IVIg infusions, may explain why this eruption occurred with the initial infusion of IVIg and not with repeated infusions.
Smith
K J
KJ
Department of Dermatology and Pathology, National Naval Medical Center, Bethesda, MD, USA.
Dutka
A L
AL
Skelton
H G
HG
D000368:Aged; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology*; D003711:Demyelinating Diseases / Q000276:immunology / Q000628:therapy*; D003875:Drug Eruptions / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects* / Q000276:immunology; D007150:Immunohistochemistry; D017512:Lichenoid Eruptions / Q000139:chemically induced* / Q000473:pathology; D008297:Male
D000888:Antibodies, Anti-Idiotypic; D016756:Immunoglobulins, Intravenous